ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 
  • Home
  • Congress Archive
    • ISTH 2022 Congress
    • ISTH 2021 Congress
    • ISTH 2020 Congress
  • Resources
  • Search

Immune Thrombocytopenic Purpura: A Case Report

A. Berisha1, S. Sadiku1

1University of Prishtina, Prishtina, Albania

Abstract Number: PB1011

Meeting: ISTH 2021 Congress

Theme: Platelets and Megakaryocytes » Platelet Function and Interactions

Background: Immune thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by a low platelet count and mucocutaneous bleeding. Immune thrombocytopenic purpura is classified as primary or as secondary to an underlying disorder and as acute (of six months or less in duration) or chronic. The diagnosis of immune thrombocytopenic purpura remains one of exclusion. Prednisone (1 mg per kilogram of body weight) is the conventional initial therapy for patients who have more severe thrombocytopenia.

Aims: The aim of this case report is to better understand ITP, including the clinical features and treatment outcome.

Methods: The data was taken from the patient files in the Hematology clinic of the clinical university center of Kosovo. The patient included in the report was diagnosed with ITP with the exclusion of other secondary causes of ITP including autoimmune disease and hematological disease. The patient was treated with the standard therapy for ITP.

Results: The patient D.H, female presented with mucocutaneous bleeding and a thrombocyte count of 36 x 10³/mm³. The immunological profile including ANA, anti-dsDNA and other markers were all negative. The viral antibody titers were negative for IgM accept for CMV IgG which was positive. The blood smear, bone marrow aspiration and biopsy no hematological disease. The patient was started on corticosteroids but the treatment was not satisfactory.

Conclusions: The patient was initially treated with prednisone for 3 weeks but the thrombocyte count did not increase. For this reason the patient was treated with Rituximab once a week. Even after taking 3 doses of Rituximab improvement. After that she was started with Azathioprine 100mg once a day.

To cite this abstract in AMA style:

Berisha A, Sadiku S. Immune Thrombocytopenic Purpura: A Case Report [abstract]. Res Pract Thromb Haemost. 2021; 5 (Suppl 2). https://abstracts.isth.org/abstract/immune-thrombocytopenic-purpura-a-case-report/. Accessed September 29, 2023.

« Back to ISTH 2021 Congress

ISTH Congress Abstracts - https://abstracts.isth.org/abstract/immune-thrombocytopenic-purpura-a-case-report/

Simple Search

Supported By:

Takeda logo

ISTH 2022 Congress site

Visit the official web site for the ISTH 2022 Virtual Congress »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2023 John Wiley & Sons, Inc. All Rights Reserved.
Wiley